Parkinson’s Disease Market Poised for Phenomenal Expansion During the Forecast Period (2023-32) – Estimates DelveInsight | AbbVie, Addex Pharma, Inhibikase, Amneal Pharma, Sunovion, Neuraly, NeuroDerm

Parkinson's Disease Market Poised for Phenomenal Expansion During the Forecast Period (2023-32) - Estimates DelveInsight | AbbVie, Addex Pharma, Inhibikase, Amneal Pharma, Sunovion, Neuraly, NeuroDerm
Delveinsight Business Research LLP
As per DelveInsight, the Parkinson’s Disease Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Parkinson’s Disease and the launch of new therapies in the market.

DelveInsight’s “Parkinson’s Disease Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Parkinson’s Disease market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Parkinson’s Disease drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Parkinson’s Disease treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Parkinson’s Disease: An Overview

Parkinson’s disease is a progressive disorder that is caused by the degeneration of nerve cells in the part of the brain called the substantia nigra, which controls movement. The cause of Parkinson’s disease remains unknown, but it has long been hypothesized that exposure to environmental risk factors may be one cause, along with an inherited susceptibility. The majority of cases are thought to arise sporadically, although up to 20% of people with Parkinson’s disease also have a first-degree relative with Parkinson’s disease.

Classic presenting features of Parkinson’s disease include motor symptoms, such as bradykinesia, rigidity, rest tremor, and postural instability. However, non-motor symptoms, such as depression, cognitive impairment, pain, and autonomic disturbances, are also often present, and they can severely affect a patient’s quality of life.

As per a global study of the Global Burden of Diseases (GBD) 2016 Parkinson’s disease, collaborators to estimate the Parkinson’s Disease prevalence. Among neurological disorders examined in the Global Burden of Disease, Injuries, and Risk Factors Study (GBD), in 2015, Parkinson’s Disease was the fastest-growing in prevalence, disability, and deaths.

Parkinson’s Disease Market Key Facts

  • The Parkinson’s Disease Market size in the 7MM was approximately USD 3,226 million in 2022, and it is projected to increase during the forecast period. As per DelveInsight, the Parkinson’s Disease Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases and the launch of new therapies in the market.

  • The Parkinson’s disease market size in the 7MM will increase at a CAGR of 11.2% due to the increase in diagnosed prevalent cases of the disease and the anticipated launch of emerging Parkinson’s disease therapies.

  • Among EU4 and the UK, Germany accounts for the maximum Parkinson’s disease market size in 2022 while the United Kingdom occupies the bottom of the ladder in 2022.

  • According to DelveInsight estimates, the US accounted for approximately 1.1 million diagnosed cases whereas in the EU4 and the UK, there were around 1.2 million diagnosed Parkinson’s disease cases in 2022.

  • Among the EU4 and the UK, Germany had the highest diagnosed prevalent population of Parkinson’s disease (approximately 0.5 million cases), followed by France (approximately 0.2 million cases) in 2022. On the other hand, Italy had the lowest diagnosed prevalent population in EU4 and the UK countries and the 7MM.

  • Japan accounted for 0.2 million diagnosed cases of Parkinson’s disease in 2022.

  • Parkinson’s disease has been identified as a male-dominant disease; in our analysis, the number of males suffering was higher as compared to females. In 2022, 54% of cases of Parkinson’s disease were in males, while 46% of cases were in females in the 7MM.

Parkinson’s Disease Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Parkinson’s Disease pipeline therapies. It also thoroughly assesses the Parkinson’s Disease market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Parkinson’s Disease drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Parkinson’s Disease Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Parkinson’s Disease epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Parkinson’s Disease epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Parkinson’s Disease Epidemiology, Segmented as –

  • Diagnosed Prevalent Population of Parkinson’s Disease in the 7MM (2019-32)

  • Gender-specific Diagnosed Prevalent Population of Parkinson’s Disease in the 7MM (2019-32)

  • Age-specific Diagnosed Prevalent Population of Parkinson’s Disease in the 7MM (2019-32)

  • Stage-specific Diagnosed Prevalent Population of Parkinson’s Disease in the 7MM (2019-32)

Parkinson’s Disease Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Parkinson’s Disease market or expected to be launched during the study period. The analysis covers the Parkinson’s Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Parkinson’s Disease drugs based on their sale and market share.

The report also covers the Parkinson’s Disease pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Parkinson’s Disease companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Parkinson’s Disease Market Will Evolve and Grow by 2032 @

Parkinson’s Disease Therapeutics Analysis

There is no standard treatment for Parkinson’s disease. Treatment for each person with Parkinson’s disease is based on their symptoms. There are many medications available to treat Parkinson’s symptoms, although none yet reverse the disease’s effects. It is common for people with Parkinson’s disease to take a variety of these medications – all at different doses and at different times of day – to manage symptoms.

The approved medication therapies are categorized into seven groups that include levodopa, carbidopa-levodopa infusion (DUOPA), dopamine agonists, MAO B inhibitors (AZILECT, XADAGO), catechol o-methyltransferase (COMT) inhibitors, anticholinergics, adenosine A2a antagonists (ISTRADEFYLLINE), and amantadine (GOCOVRI, OSMOLEX ER). The treatment is given based on the stages of the disease, symptoms shown, and those who are already receiving some medication. Based on the mentioned criteria, the treatment can be classified into early-stage, late-stage, and non-motor symptoms.

To counter unmet market needs and provide better treatment choices for PD, several market players are working robustly either on single-agent novel molecules or on combination and dose modification of standard therapies. Several therapies are expected to be launched in the near future.

Currently, Cerevel Therapeutics is leading the therapeutics market with its Parkinson’s disease drug candidates in the most advanced stage of clinical development.

Parkinson’s Disease Companies Actively Working in the Therapeutics Market Include

Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., NeuroDerm Ltd., Pharma Two B, Serina Therapeutics, Sun Pharma Advanced Research Company Limited, CuraSen Therapeutics, Inc., Takeda, Xoc Pharmaceuticals, Sumitomo Pharma Co., Ltd., XWPharma, Athira Pharma, Aptinyx, VistaGen Therapeutics, Inc., 1ST Biotherapeutics, Inc., Novo Nordisk A/S, AstraZeneca, MedImmune, Anavex Life Sciences Corp., Living Cell Technologies, Intra-Cellular Therapies, Inc., Alkahest, Inc., Kissei Pharmaceutical Co., Ltd., and many others.

Emerging and Marketed Parkinson’s Disease Therapies Covered in the Report Include:

  • ABBV-951: AbbVie

  • Azilect: Teva Pharmaceuticals

  • Dipraglurant: Addex Pharma S.A.

  • Duopa (Carbidopa and Levodopa- ES): AbbVie

  • Gocovri: Adamas Pharmaceuticals

  • Haruropi Tape (Ropinirole HCL Transdermal Patch): Hisamitsu Pharmaceutical Co. Inc.

  • IkT-148009: Inhibikase Therapeutics

  • Inbrija (Levodopa): Acorda Therapeutics Inc.

  • IPX203: Amneal Pharmaceuticals

  • Kynmobi: Sunovion Pharmaceuticals

  • Mesdopetam/IRL790: Integrative Research Laboratories AB

  • ND0612: Mitsubishi Tanabe Pharma

  • NLY01: Neuraly

  • Nourianz (Istradefylline): Kyowa Kirin

  • Nuplazid (Pimavanserin): Acadia Pharmaceuticals, Inc.

  • Ongentys: Neurocrine Biosciences

  • Osmolex ER: Adamas Pharmaceutical

  • P2B001: Pharma Two B

  • Posiphen: Annovis Bio Inc.

  • PT320: Peptron

  • Tavapadon (CVL-751/PF-06649751): Cerevel Therapeutics

  • Xadago (Safinamide): Newron Pharmaceuticals

And many more

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Parkinson’s Disease Competitive Intelligence Analysis

4. Parkinson’s Disease Market Overview at a Glance

5. Parkinson’s Disease Background and Overview

6. Parkinson’s Disease Patient Journey

7. Parkinson’s Disease Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Parkinson’s Disease Treatment Algorithm, Current Treatment, and Medical Practices

9. Parkinson’s Disease Unmet Needs

10. Key Endpoints of Parkinson’s Disease Treatment

11. Parkinson’s Disease Marketed Therapies

12. Parkinson’s Disease Emerging Drugs and Latest Therapeutic Advances

13. Parkinson’s Disease Seven Major Market Analysis

14. Attribute Analysis

15. Parkinson’s Disease Market Outlook (In US, EU5, and Japan)

16. Parkinson’s Disease Companies Active in the Market

17. Parkinson’s Disease Access and Reimbursement Overview

18. KOL Views on the Parkinson’s Disease Market

19. Parkinson’s Disease Market Drivers

20. Parkinson’s Disease Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Peripheral Vascular Devices Market

The global Peripheral Vascular Devices market was valued at USD 9.63 billion in 2022, growing at a CAGR of 7.88% during the forecast period from 2023 to 2028, to reach USD 15.13 billion by 2028. Some of the key players such as Medtronic, Boston Scientific Corporation, B. Braun Melsungen AG, Braile Biomedica, JOTEC GmbH, Edwards Life Sciences Corporation, LeMaitre Vascular, Inc., W. L. Gore & Associates, Inc, Abbott, Cardiovascular Systems, Inc., AngioDynamics Inc, Control Medical Technology, LLC, Walk Vascular, LLC, Transit Scientific, Conic Vascular, and others are actively working in the Peripheral Vascular Devices Market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States